YARROW BIOSCIENCE, INC. Cost of Revenue
YARROW BIOSCIENCE, INC. (YARW) reported Cost of Revenue of $24.88 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2021-03-04
- YARROW BIOSCIENCE, INC. cost of revenue for the quarter ending 2020-12-31 was $24.88M.
- YARROW BIOSCIENCE, INC. cost of revenue for the quarter ending 2020-09-30 was $26.76M, a 15.35% increase year-over-year.
- YARROW BIOSCIENCE, INC. cost of revenue for the quarter ending 2020-06-30 was $178.87M, a 823.94% increase year-over-year.
- YARROW BIOSCIENCE, INC. cost of revenue for the quarter ending 2020-03-31 was $41.64M, a 157.16% increase year-over-year.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | $24.88M 10-K · filed 2021-03-04 | $51.64M derived: sum of 2 quarters · filed 2021-03-04 | $230.51M derived: sum of 3 quarters · filed 2021-03-04 | $272.15M derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-09-30 | $26.76M 10-K · filed 2021-03-04 | $205.63M derived: sum of 2 quarters · filed 2021-03-04 | $247.26M derived: sum of 3 quarters · filed 2021-03-04 | $247.26M derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-06-30 | $178.87M 10-K · filed 2021-03-04 | $220.50M derived: sum of 2 quarters · filed 2021-03-04 | $220.50M derived: sum of 3 quarters · filed 2021-03-04 | $243.70M derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-03-31 | $41.64M 10-K · filed 2021-03-04 | $41.64M derived: sum of 2 quarters · filed 2021-03-04 | $64.84M derived: sum of 3 quarters · filed 2021-03-04 | $84.20M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 | $23.20M derived: sum of 2 quarters · filed 2021-03-04 | $42.56M derived: sum of 3 quarters · filed 2021-03-04 | $58.75M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-09-30 | $23.20M 10-K · filed 2021-03-04 | $42.56M derived: sum of 2 quarters · filed 2021-03-04 | $58.75M derived: sum of 3 quarters · filed 2021-03-04 | |
| 2019-06-30 | $19.36M 10-K · filed 2021-03-04 | $35.55M derived: sum of 2 quarters · filed 2021-03-04 | ||
| 2019-03-31 | $16.19M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |